LYEL Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -124.5%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Insmed, Inc.'s return on equity of -192.35%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 28.93%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 41.68%. Given that Insmed, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Insmed, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 83,438.97x versus 49.20x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -301.29%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Nektar Therapeutics's return on equity of -327.67%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 28.93%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 97.05%. Given that Nektar Therapeutics has higher upside potential than Lyell Immunopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 83,438.97x versus 67.95x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of 21.74%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 28.93%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 12.87%. Given that Lyell Immunopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Lyell Immunopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.94 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 83,438.97x versus 5.84x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of 36.91%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 28.93%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $532.96 which suggests that it could grow by 11%. Given that Lyell Immunopharma, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Lyell Immunopharma, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 83,438.97x versus 10.26x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.